AARD vs TXT · $284.4M cap vs P/E 19, rev $7.52B
Aardvark Therapeutics, Inc. Common Stock (AARD) versus Textron Inc (TXT) — a side-by-side from cached financials, not a winner call.
Aardvark Therapeutics, Inc. Common Stock (AARD) is a biotechnology company listed on US.
Textron Inc (TXT) is a aerospace & defense company listed on US.
Latest reported AARD revenue for 2025-12-31 was $0. Net income was -$57.6M. Revenue was down 100.0% from 2024-12-31 to 2025-12-31. AARD currently screens at market cap $284.4M.
Latest reported TXT revenue for 2026-07-04 was $7.52B. Net income was $468.0M. TXT currently screens at market cap $14.85B and trailing P/E 18.5.
AARD currently screens at market cap $284.4M. TXT currently screens at market cap $14.85B and trailing P/E 18.5.
Not investment advice. Open the AARD and TXT stock pages for the full models.
Not investment advice.